Navigation Links
Mayo Clinic tests novel vaccine for aggressive brain tumors
Date:10/22/2007

JACKSONVILLE, Fla. − A vaccine that has significantly increased life expectancy in early tests of patients with glioblastoma multiforme (GBM) − the most common, most aggressive form of brain cancer in adults − is now being offered through a clinical trial at Mayo Clinic in Jacksonville.

The vaccine represents a fresh and fairly simple approach to treating this cancer, says neurosurgeon Kent New, M.D., Ph.D., who will be leading the study at Mayo. About 40% of these tumors display a particular protein on their surface and the vaccine is designed to trick the patients immune system into thinking the protein is foreign in order to mount a killing response.

We are pleased to have a new and promising therapy to offer patients who want to participate in this clinical trial, says Dr. New. The results, so far, have exceeded expectations.

Earlier studies of the vaccine at the University of Texas M. D. Anderson Cancer Center and Duke University Medical Center showed that median survival for the 39 GBM patients tested increased by more than 50 percent compared to the typical outcome. Additionally, the time it took tumors to begin growing again was doubled.

Dr. New cautioned, however, that it is unknown whether the vaccine added to standard treatment (surgery followed by radiation and chemotherapy) will ultimately produce any better outcome than the standard treatment alone. By comparing standard therapy plus the vaccine to standard therapy alone, we hope to determine the true benefit of the vaccine he says.

According to the National Cancer Institute, more than 20,000 people in the U.S. will be diagnosed with a brain tumor in 2007 and almost 13,000 will die from the cancer. GBM, the most common primary brain tumor, is considered incurable; most patients die within a year of diagnosis.

Twenty or more centers nationwide will participate in the clinical trial initially, which is being sponsored by Celldex Therapeutics, the manufacturer of the vaccine, known as CDX-110. The study will be conducted in two stages. Approximately 90 patients will participate in the first portion, and if results show an improvement in disease-free survival for the CDX-110 treated patients, an additional 285 participants will be enrolled in the expanded study, which will include more sites.

Patients newly diagnosed with GBM who enroll in the study will have surgery at the participating center, and tumors will be examined to see if they express the mutated epidermal growth factor receptor variant III (EGFRvIII) protein. Researchers believe that this protein, which is not expressed on normal brain cells, pushes cancer development, which is one reason why glioblastomas are so aggressive. The vaccine uses synthetic versions of EGFRvIII to stimulate both cell-mediated immunity (T cells that attack invaders) and humoral immune responses (B cells that provide ongoing immune surveillance).

Participating patients whose tumors exhibit EGFRvIII will be randomized (selected by chance) either to standard treatment alone or standard treatment plus CDX-110, and the agents will be used until the tumor progresses or patients develop side effects from the treatment.


'/>"/>

Contact: Cynthia Nelson
nelson.cynthia1@mayo.edu
904-953-0464
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. How do patients benefit of clinical trials
3. Magnetic resonance angiography in clinical medicine
4. Clinical trials need to be more frank
5. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
6. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
7. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
8. Clinical Comparisons Between ADHD Drugs Are Less
9. Specialized Clinics For Manipurs AIDS Patients
10. Outsourcing clinical trials to India
11. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
Breaking Medicine Technology: